# Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

> **NCT00102817** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 149 (actual)

## Conditions studied

- Growth Hormone Disorder
- Pituitary Dwarfism

## Interventions

- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT00102817
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102817, "Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00102817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*